Robert Greenberg

Executive Chairman
Alfred Mann Foundation

Dr. Greenberg is the Executive Chairman of The Alfred E. Mann Foundation for Scientific Research, an independent non-profit medical device incubator committed to developing and commercializing innovative solutions for significant unmet or poorly met medical conditions. Dr. Greenberg was previously CEO and Chairman of Second Sight Medical Products (EYES), a company he led as CEO from its inception in 1998 through 2015. Under Dr. Greenberg’s leadership, Second Sight, which Dr. Greenberg co-founded while working at the Alfred E. Mann Foundation, successfully developed and marketed an implantable retinal prosthesis, the Argus II, the world’s most advanced implantable neural stimulator, which restores useful vision to patients blinded by Retinitis Pigmentosa, allowing them to achieve greater independence. He oversaw the FDA approval, unprecedented outpatient Medicare reimbursement of approximately $150k, with sales rising to a $10M annualized run-rate, and a successful IPO on NASDAQ, with a $550M market cap at the end of his CEO tenure. More recently, while Chairman at Second Sight, Dr. Greenberg oversaw the successful development and human implantation of a wireless cortical visual prosthesis, the Orion, which has the potential to eliminate nearly all forms of blindness. Dr. Greenberg was also an Independent Director at Pulse Biosciences (PLSE), a company developing therapies based on nanosecond pulsed electric field technologies for oncology and dermatology applications. He was a Medical Reviewer at the Food and Drug Administration’s Office of Device Evaluation. Dr. Greenberg is also currently the Chairman of the Board of Directors at the Southern California Biomedical Council, a nonprofit trade association supporting the healthcare industry in the Greater Los Angeles region.